Lake Street Maintains Buy on Rezolute, Raises Price Target to $12
Lake Street analyst Daniel Brims maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $9 to $12.
Stocks · News reference
FDA Recommends Meeting for Rezolute Drug for Rare Blood Sugar Disorder Despite Missed Endpoints
Rezolute (NASDAQ: RZLT) shares surged after the FDA recommended a pre-BLA meeting for its congenital hyperinsulinism drug, ersodetug.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citizens Maintains Market Outperform on Rezolute, Raises Price Target to $15
Citizens analyst Jason N. Butler maintains Rezolute (NASDAQ:RZLT) with a Market Outperform and raises the price target from $11 to $15.
This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Analysts upgraded Boyd Gaming, NeoGenomics, PENN Entertainment, XP and Rezolute, raising targets for several names.
Cantor Fitzgerald Upgrades Rezolute to Overweight
Cantor Fitzgerald analyst Pete Stavropoulos upgrades Rezolute (NASDAQ:RZLT) from Neutral to Overweight.